Toshitaka Yajima

AstraZeneca (Japan) — Japan

Medicine · Health Sciences

27h-index2.6kcitations101works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(25), Potassium and Related Disorders(23), Diabetes Management and Research(14), Viral Infections and Immunology Research(14), Heart Failure Treatment and Management(10)

Publications100 total

Treatment Patterns and Trajectories in Patients After Acute Heart Failure Hospitalization
ESC Heart Failure·2023· 8 citedOpen Access
Impact of treatment of hyperkalaemia on quality of life: design of a prospective observational cohort study of long-term management of hyperkalaemia in patients with chronic kidney disease or chronic heart failure in Japan
BMJ Open·2023· 3 citedOpen Access
Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study
Frontiers in Physiology·2023· 1 citedOpen Access
Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
Journal of Clinical Medicine·2023Open Access
Association of Hyperkalemia and Hypokalemia with Patient Characteristics and Clinical Outcomes in Japanese Hemodialysis (HD) Patients
Journal of Clinical Medicine·2023· 5 citedOpen Access
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Frontiers in Endocrinology·2023· 22 citedOpen Access
Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
BMC Nephrology·2023· 42 citedOpen Access
Additional file 1 of Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
Figshare·2023Open Access
Andexanet alfa (ONDEXXYA<sup>®</sup> for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence
Folia Pharmacologica Japonica·2022· 4 citedOpen Access
Machine learning models for prediction of HF and CKD development in early-stage type 2 diabetes patients
Scientific Reports·2022· 17 citedOpen Access
Abstract 11780: Machine Learning Models to Predict Development of CKD and/or HF in Early Stages of Type 2 Diabetes Patients
Circulation·2022
Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia
Nutrients·2022· 13 citedOpen Access
Impact of Chronic Potassium Binder Treatment on Clinical Outcome in Patients With Hyperkalemia: A Nationwide Hospital-Based Cohort Study
Journal of the American Society of Nephrology·2022
Impact of Urinary Protein Examination on Early Diagnosis of CKD: A Nationwide Hospital-Based Observational Study in Japan, REAL-CKD
Journal of the American Society of Nephrology·2022
Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
Journal of Clinical Medicine·2022· 8 citedOpen Access
Validation of a new instrument for measuring disease-specific quality of life: A pilot study among patients with chronic kidney disease and hyperkalemia
Annals of Clinical Epidemiology·2022· 7 citedOpen Access
Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment
The Journal of Clinical Endocrinology & Metabolism·2022· 2 citedOpen Access
Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan
Diabetes Therapy·2022· 18 citedOpen Access
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
Diabetes Obesity and Metabolism·2022· 40 citedOpen Access
Author response for "Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries"
2022
page 1 of 5Next →

Frequent Co-authors

Kirk U. Knowlton(14), Suguru Okami(10), Shun Kohsaka(9), Nancy D. Dalton(8), Dingding Xiong(7), Yusu Gu(6), Kirk L. Peterson(6), Hideo Yasukawa(6), Eiichiro Kanda(6), Ju Chen(5), Johan Bodegård(5), Marcus Thuresson(5), Takashi Kadowaki(5), Masahiko Hoshijima(5), Naoki Kashihara(5), Issei Komuro(4), Hervé Duplain(4), Mitsuo Iwatate(4), Kenneth R. Chien(4), Eiichi Araki(4)